You are here: Industry Insights > Market News > CanSino gets COVID-19 vaccine patent from China’s IP regulator

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

HydroLinX® Antifoam Emulsion

HydroLinX® Water for Injection in Bags

Crude Semaglutide

Clopidogrel Sulfate

Carbocisteine

HydroLinX® Buffer Solutions and Process Liquids

CanSino gets COVID-19 vaccine patent from China’s IP regulator

expresspharmaAugust 18, 2020

Tag: CanSino , COVID-19 vaccine , Ad5-nCoV

Favorites

CanSino Biologics has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, reported state media, citing documents from the country’s intellectual property regulator.

It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People’s Daily reported.

The paper cited documents published by China’s National Intellectual Property Administration saying that the patent was issued on August 11.

Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.

Previous:India’s CMO market is hotbed for global PE investment: GlobalData

Next:TFF Pharmaceuticals Signs Worldwide Licensing Agreement with Union Therapeutics

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

CanSino gets COVID-19 vaccine patent from China’s IP regulator | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

CanSino gets COVID-19 vaccine patent from China’s IP regulator

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

CanSino gets COVID-19 vaccine patent from China’s IP regulator

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>